Polysomy of chromosomes 1 and 19: An underestimated prognostic factor in oligodendroglial tumors

Journal of Neuro-Oncology

Volumn 120, Issue 1, 2014, Pages 131-138

  Jiang, Haihui ^a   Ren, Xiaohui ^a   Zhang, Zhe ^a   Zeng, Wei ^a   Wang, Junmei ^b   Lin, Song ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

1p 19q; Deletion; Oligodendroglial tumors; Polysomy; Survival

Indexed keywords

NIMUSTINE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIAL TUMOR; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYSOMY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; WORLD HEALTH ORGANIZATION; BRAIN NEOPLASMS; CANCER GRADING; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84910130476     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1526-y     Document Type: Article

References (19)

1. Schwartzbaum JA, Fisher JL, Aldape KD et al (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2(494–503):1–516
2. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850
3. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861
4. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
5. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
6. Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492–504
7. Snuderl M, Eichler AF, Ligon KL et al (2009) Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 15:6430–6437
8. Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831–1836
9. Kujas M, Lejeune J, Benouaich-Amiel A et al (2005) Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322–326
10. Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22:3133–3138
11. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722
12. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
13. Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9:717–726
14. Wiens AL, Cheng L, Bertsch EC et al (2012) Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases. J Neuropathol Exp Neurol 71:618–624
15. Ren X, Jiang H, Cui X et al (2013) Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. Neuro Oncol 15:1244–1250
16. Heegaard S, Sommer HM, Broholm H et al (1995) Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76:1809–1813
17. Kros JM, Hop WC, Godschalk JJ et al (1996) Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78:1107–1113
18. Hagel C, Krog B, Laas R et al (1999) Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas. J Exp Clin Cancer Res 18:305–309
19. Theeler BJ, Yung WK, Fuller GN et al (2012) Moving toward molecular classification of diffuse gliomas in adults. Neurology 79:1917–1926